Advanced Otolaryngology PC — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$5,357	3
2024	Research	$26,116	111
2023	Research	$66,694	134
2022	Research	$10,487	9
2021	Research	$17,109	3
2020	Research	$5,435	2
2019	Research	$44,329	2

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca Pharmaceuticals LP $76,163 9 payments
GlaxoSmithKline, LLC. $54,498 26 payments
Regeneron Pharmaceuticals, Inc. $44,866 229 payments

Studies the money was for Research payments · program years 2019–2025

A Multicenter Randomized Double Blind Parallel Group Placebo Controlled Phase 3 Efficacy and Safety Study Of Benralizumab in Patients with Severe Nasal Polyposis OSTRO $63,274 6 payments
A Randomised, Double-Blind, Parallel Group Phase III Study to Assess T $54,498 26 payments
Assessing Long-Term Outcomes of DUPIXENT Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyposis (AROMA) $44,866 229 payments
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo- Controlled Phase 3 Efficacy and Safety Study of Benralizumab in Patients with Eosinophilic Chronic Rhinosinusitis with Nasal Polyps (ORCHID) $9,289 2 payments
A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Benralizumab for the Prevention of Recurrence of Nasal Polyps Following Surgical Removal in Patients with Chronic Rhinosinusitis with Nasal Polyps (OXALIS) $3,600 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.